20 research outputs found

    Acute hepatitis B due to immune-escape mutations in a naturally immune patient

    No full text
    Incidence of hepatitis B virus infection (HBV) has been greatly reduced globally after the introduction of universal vaccination programs. However, another potential threat was noticed almost 2 decades ago, which is the selection of antibody escape HBV strains. Antibody or immune escape strains of HBV carry mutations in the S gene which encodes "a" determinant region located at amino acid positions 124 to 149. Certain mutations in this region, which promotes antibody response, might lead to an alteration in the antigenicity of hepatitis B surface antigen (HBsAg). Anti-HBs might fail to neutralize the mutant virus and transmission or reappearance of infection in previously immunized individuals can be possible. Herein, we report a patient with known HBV seropositivity (HBsAg negative, anti-HBs positive, anti-HBc IgG positive) for more than 10 years who developed a symptomatic acute hepatitis due to occurrence of immune escape mutants in the absence of any immunosuppression or cytotoxic chemotherapy. To the best of our knowledge, this is the first reported case of acute hepatitis B due to escape mutations in a naturally immune patient

    Frequency of Clamydia pneumoniae and Mycoplasma pneumoniae infections in children

    No full text
    Objective: Chlamydia pneumoniae and Mycoplasma pneumoniae are among the most important pathogens of acute respiratory infections in children between the ages of 5 and 15 years. We aimed to investigate seasonal frequency of respiratory infections caused by C. pneumoniae and M. pneumoniae, frequnecy of coinfection, clinical findings and to determine relationship between clinical findings and laboratory results

    Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B

    No full text
    We sought to evaluate the long-term results of interferon-alpha (IFN-alpha) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Eighty HBeAg-negative naive patients (62 men; mean age, 39.9 years) who received IFN-alpha for 6 months were studied. Alanine aminotransferase normalization with undetectable HBV-DNA by molecular hybridization was accepted as response. All patients but 1 were precirrhotic stage. At the end of treatment, 44 (55%) patients responded, and they were followed for a mean of 59.5 months (range, 18-132). Twenty-seven patients (61.4%) showed recurrence (63% in first year). Responses at 6 months and at the end of the follow-up period 42.5% and 30% (including 7 patients without end treatment response), respectively. Recurrence of HBV replication was not detected after the 2-years follow-up period. Histologic improvement was observed in 83.3% patients with end-of-follow-up response. HBsAg became negative in 4 patients (5%). On multivariate analysis, younger age (P=.04) and lower GGT level (P=.037) were independent factors for prediction of end-of-follow-up response. Nearly half of the patients with HBeAg-negative chronic hepatitis B responds to IFN-alpha at the end of therapy. Despite the high recurrence rates, response continues in about one third of patients after a mean of 59.5 months

    Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey

    No full text
    There is little information about the prevalence of occult hepatitis B virus infection (OHBVI). We have investigated the prevalence and virological features of OHBVI among female sex workers (FSWs) in Istanbul

    Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy

    No full text
    Background and study aims : To investigate the efficacy of the combined therapy of lamivudine (LAM) plus alpha interferon (IFN) and LAM monotherapy in HBeAg negative chronic hepatitis B (CHB) patients who were unresponsive to previous IFN monotherapy, and the incidence of YMDD mutations
    corecore